Canket Stats & Data

Identity/label confusion is common: multiple community and lab-reanalysis posts indicate that many samples sold as “FXE” have actually been 2′-fluoro-2-oxo‑PCE (a.k.a. 2F‑NENDCK/“CanKet”). This makes potency, duration, and interaction risks less predictable; drug checking is strongly advised before setting doses. Reports consistently describe rapid onset, short-to-moderate dissociation, and a tendency toward stimulation or restlessness compared with ketamine, which can encourage redosing; pre‑measuring doses and setting a session limit can reduce escalation. Like other arylcyclohexylamines, heavy or frequent use may contribute to ketamine‑type cystitis/uro‑toxicity (urgency, frequency, suprapubic pain); spacing sessions by weeks, staying within conservative doses, and seeking care if urinary symptoms appear are prudent. Combining with CNS depressants (alcohol, opioids, GHB) markedly increases blackout, aspiration, and respiratory depression risk; if someone becomes unresponsive, place in the recovery position and seek help. Stimulant combinations increase tachycardia, agitation, and manic states; avoid if possible or keep doses very low with sober monitoring. Because many “FXE” samples are actually 2F‑2′‑oxo‑PCE, and some batches show atypical effects, treat reagent color changes and appearance as non‑diagnostic; only lab‑grade analysis (FTIR/GC‑MS/LC‑MS) can confirm identity. Nasal use can irritate mucosa; use fine powders, alternate nostrils, and rinse with saline post‑session to reduce damage. Very limited pharmacokinetic data exist; assume driving/complex tasks are unsafe for at least a full waking cycle after significant doses.